Author(s):
Adsul Samruddhi Subhash, waable Madhuri Sanjay, Gayke Sanket Ramesh, Bhand Revannath Narayan, Waghmare sweeti Mohan
Email(s):
samuadsul003@gmail.com
DOI:
10.52711/2231-5659.2026.00025 
Address:
Adsul Samruddhi Subhash, waable Madhuri Sanjay, Gayke Sanket Ramesh, Bhand Revannath Narayan, Waghmare sweeti Mohan
Swastyadarpan Pratishthan’s Shantiniketan College of Pharmacy, A/P Dhotre (B.K.), Tal. Parner, Ahmednagar, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 2,
Year - 2026
ABSTRACT:
In order to fight illness and lessen human suffering, medicine is essential. Pharmaceuticals certainly have therapeutic advantages, but they also carry the risk of Adverse Drug Reactions (ADRs), which are undesirable side effects that can happen at normal dosages. The World Health Organization (WHO) states that adverse drug reactions (ADRs) can cause anything from little discomfort to serious, perhaps fatal consequences. Given India's standing as the "pharmacy of the world," it is critical to have a strong and adaptable pharmacovigilance system in place to protect public health. In India, pharmacovigilance serves as the main framework for identifying, evaluating, disclosing, and averting adverse drug reactions. It places a strong emphasis on post-marketing surveillance to guarantee medications' ongoing safety. To better handle reporting across a large population, the program, which was first run by AIIMS, New Delhi, switched to the Indian Pharmacopoeia Commission in 2011. India's PvPI, which is backed by WHO's worldwide network via the Uppsala Monitoring Centre (UMC) and online resources like VigiFlow and VigiLyze, encourages medical professionals and the general people to report any suspected adverse drug reactions (ADRs), regardless of how severe or unknown they may be. Through mobile applications, toll-free helplines, online forms, and support for vernacular languages, PvPI has made the reporting process easier and more accessible. In addition to improving medication safety profiles, reporting lowers treatment expenses, negative outcomes, and hospital readmissions. To guarantee the safety of medications, a culture of ADR reporting is necessary. Each report helps to safeguard lives and improve the healthcare system.
Cite this article:
Adsul Samruddhi Subhash, waable Madhuri Sanjay, Gayke Sanket Ramesh, Bhand Revannath Narayan, Waghmare sweeti Mohan. Reporting ADR: A Step towards patient safety. Asian Journal of Research in Pharmaceutical Sciences.2026; 16(2):161-6. doi: 10.52711/2231-5659.2026.00025
Cite(Electronic):
Adsul Samruddhi Subhash, waable Madhuri Sanjay, Gayke Sanket Ramesh, Bhand Revannath Narayan, Waghmare sweeti Mohan. Reporting ADR: A Step towards patient safety. Asian Journal of Research in Pharmaceutical Sciences.2026; 16(2):161-6. doi: 10.52711/2231-5659.2026.00025 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2026-16-2-10
REFERENCES:
1. Suke SG, Kosta P, Negi H. Role of pharmacovigilance in India: An overview. Online journal of public health informatics. 2015 Jun 22; 7(2).
2. Almandil NB. Healthcare professionals’ awareness and knowledge of adverse drug reactions and pharmacovigilance. Saudi medical journal. 2016 Dec; 37(12):1359.
3. Shetty A, Dubey A, Matcheswala A, Bangera S. Pharmacovigilance Systems and Strategies: Importance of Post-Marketing Surveillance for Ensuring Drug Safety and Patient Health in Europe, United States, and India. Authorea Preprints. 2023 Feb 25.
4. Khan MS, Mishra A, Giri IC, Pujari NM. Role of ADR Reporting Culture in Advancing Patient Safety: A Review of Challenges and Solutions. Journal of Drug Discovery and Health Sciences. 2024 Dec 30; 1(04):178-86.
5. Mittal N, Mittal R, Gupta MC. An overview of the pharmacovigilance system in India. Clinical research and regulatory affairs. 2016 Jan 2; 33(1):4-8.
6. Bhat S, Dubey S, Gavade R, Dhupkar P, Shetti G. India-Pharmacy of the World. Quest Journal of Management. 2021 Mar 1; 12(1):42-8.
7. Girase AM, Mahale BM, Patil NM. Pharmacovigilance. Research Journal of Science and Technology. 2025; 17(1):41-7.
8. Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicologic Pathology. 2005 Jan; 33(1):155-64.
9. Alomar M, Tawfiq AM, Hassan N, Palaian S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Therapeutic advances in drug safety. 2020 Aug; 11:2042098620938595.
10. Prakash J, Sachdeva R, Shrivastava TP, Jayachandran CV, Sahu A. Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India. Indian Journal of Pharmacology. 2021 Mar 1; 53(2):143-52.
11. Munshi R, Maurya M. Impact of Educational Intervention on the Knowledge, Attitude, and Practice of Pharmacovigilance Among Nurses at a Tertiary Care Public Hospital. Current Drug Safety. 2023 Feb 1; 18(1):31-8.
12. Bhuvaneshwari E, Chakradhar T, Sravani M. Analysis of spontaneous individual case safety reports reported at adverse drug reaction monitoring centre: tertiary care teaching hospital in South India. International Journal of Basic & Clinical Pharmacology. 2019 Nov; 8(11):2541.
13. Cukier K, Mayer-Schoenberger V. The rise of big data: How it’s changing the way we think about the world. The best writing on mathematics. 2014; 2014:20-32
14. Rajesh D, Thejaswini M. Drug Safety Alerts Issued by the National Coordination Centre for Pharmacovigilance Programme of India: Current Practices and Future Recommendations. Asian Journal of Pharmaceutical Research and Health Care. 2023 Jan 1; 15(1):64-9.
15. Pulford J, Abomo P, Liani M, Murunga V, Tagoe N, Kinyanjui S, Molyneux S, Nyamongo I, Oronje R, Tolhurst R, Bates I. DELTAS Africa Learning Research Programme: Learning Report No. 3 (Apr 2018–Mar 2019).
16. Doshi N, Prajapati B, Selvaraj L. A Pharmacovigilance Study on Adverse Drug Reaction Profile at a Tertiary Care Teaching Hospital from Western Part of India. International Journal of Pharmaceutical Investigation. 2025 Apr 1; 15(2).
17. Singh P, Vaishnav Y, Verma S. Development of pharmacovigilance system in India and paradigm of pharmacovigilance research: an overview. Current Drug Safety. 2023 Nov 1; 18(4):448-64.
18. Simion D, Postolache F, Fleacă B, Fleacă E. Ai-driven predictive maintenance in modern maritime transport—Enhancing operational efficiency and reliability. Applied Sciences. 2024 Oct 16; 14(20):9439.
19. Montané E, Santesmases J. Adverse drug reactions. Medicina Clínica (English Edition). 2020 Mar 13; 154(5):178-84.
20. Schatz S, Weber RJ. Adverse drug reactions. Pharmacy Practice. 2015 Aug 24; 1(1):16-23.
21. Geer MI, Koul PA, Tanki SA, Shah MY. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital. Journal of pharmacological and toxicological methods. 2016 Sep 1; 81:323-34.
22. Srisuriyachanchai W, Cox AR, Jarernsiripornkul N. Exploring healthcare professionals’ practices and attitudes towards monitoring and reporting of severe adverse drug reactions. InHealthcare 2022 Jun 10 (Vol. 10, No. 6, p. 1077). MDPI.
23. Izuka U, Ojo GG, Ayodeji SA, Ndiwe TC, Ehiaguina VE. Powering rural healthcare with sustainable energy: a global review of solar solutions. Engineering Science & Technology Journal. 2023 Oct 17; 4(4):P-No.
24. Burke SP, Stratton K, Baciu A, editors. The future of drug safety: promoting and protecting the health of the public. National Academies Press; 2007 Mar 27.
25. Letourneau M, Wells G, Walop W, Duclos P. Improving global monitoring of vaccine safety: a survey of national centres participating in the WHO Programme for International Drug Monitoring. Drug safety. 2008 May; 31(5):389-98.
26. Jain S, Jain VK, Jain V, Sharma R. Modern approaches in pharmacovigilance system in India to assuring drug safety. For healthcare professionals: scope and opportunities. 2020:151.
27. Rayón-Ramírez G, Alvarado-López S, Camacho-Sandoval R, Loera MJ, Svarch AE, Alcocer-Varela J. Strengthening the pharmacovigilance system in Mexico: Implementation of VigiFlow and VigiLyze, as ICSR and signal detection management systems. Pharmaceutical Medicine. 2023 Nov; 37(6):425-37.
28. Polishchuk A. Exploring the challenges in the harmonization of clinical evaluation of medical device software across EU member states.
29. Fitzgerald MC. A Global Framework of National Quality PV Practitioner Certification Programs. InSixteenth European Photovoltaic Solar Energy Conference 2020 Nov 25 (pp. 2936-2939). Routledge.
30. Sharma M, Baghel R, Thakur S, Adwal S. Surveillance of adverse drug reactions at an adverse drug reaction monitoring centre in Central India: a 7-year surveillance study. BMJ open. 2021 Oct 1; 11(10):e052737.
31. Katyal S, Srivastav S, Katoch O, Rodrigues C, Rupali P, Chakrabarti A, Ray P, Biswal M, Tak V, Nath R, Mukhopadhyay C. A self-reported survey on the implementation of infection prevention and control elements in Indian hospitals, part of a HAI surveillance network: Results from 23 hospitals conducting a standardized IPC assessment. American Journal of Infection Control. 2023 Jan 1; 51(1):29-34.
32. Mahajan MM, Thatte UM, Gogtay NJ, Deshpande S. An analysis of completeness and quality of adverse drug reaction reports at an adverse drug reaction monitoring centre in Western India. Perspectives in Clinical Research. 2018 Jul 1; 9(3):123-6.
33. Adedeji AA, Sanusi B, Tella A, Akinsanya M, Ojo O, Akinwunmi MO, Tikare OA, Ogunwande IA, Ogundahunsi OA, Ayilara OO, Ademola TT. Exposure to anti-malarial drugs and monitoring of adverse drug reactions using toll-free mobile phone calls in private retail sector in Sagamu, Nigeria: implications for pharmacovigilance. Malaria journal. 2011 Aug 9; 10(1):230.
34. Doomra R, Inder D, Kumar P. Way forward to pharmacovigilance and adverse drug reaction monitoring in India: A critical review. Journal of Integrative Medicine and Research. 2025 Apr 1; 3(2):91-6.
35. Jordan S, Logan PA, Panes G, Vaismoradi M, Hughes D. Adverse drug reactions, power, harm reduction, regulation and the ADRe profiles. Pharmacy. 2018 Sep 18; 6(3):102.
36. Davies EC, Green CF, Mottram DR, Rowe PH, Pirmohamed M. Emergency re‐admissions to hospital due to adverse drug reactions within 1 year of the index admission. British journal of clinical pharmacology. 2010 Nov; 70(5):749-55.
37. Olsen S, Neale G, Schwab K, Psaila B, Patel T, Chapman EJ, Vincent C. Hospital staff should use more than one method to detect adverse events and potential adverse events: incident reporting, pharmacist surveillance and local real-time record review may all have a place. BMJ Quality & Safety. 2007 Feb 1; 16(1):40-4
38. Rorat M, Thannhauser A, Jurek T. Analysis of injuries and causes of death in fatal farm-related incidents in Lower Silesia, Poland. Annals of agricultural and environmental medicine. 2015; 22(2)..
39. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. Adverse drug events occurring following hospital discharge. Journal of general internal medicine. 2005 Apr; 20(4):317-23.
40. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Lippincott Williams & Wilkins; 2011.
41. Kalaiselvan V, Sharma S, Singh GN. Adverse reactions to contrast media: An analysis of spontaneous reports in the database of the pharmacovigilance programme of India. Drug safety. 2014 Sep; 37(9):703-10.
42. Bogolubova S. Knowledge, Attitudes and Practices of Nurses and Pharmacists towards Adverse Drug Reaction Reporting in the Private Sector (Master's thesis, University of the Witwatersrand, Johannesburg (South Africa)).
43. Benjamin DM. Reducing medication errors and increasing patient safety: case studies in clinical pharmacology. The Journal of Clinical Pharmacology. 2003 Jul; 43(7):768-83.
44. Nawi RA, Yasin B, Champion IC. Impromptu: great impromptu speaking is never just impromptu. Studies in English Language and Education. 2015 Oct 1; 2(2):144-57.
45. Smith HJ, Keil M. The reluctance to report bad news on troubled software projects: a theoretical model. Information Systems Journal. 2003 Jan; 13(1):69-95.
46. Aung AK, Tang MJ, Adler NR, de Menezes SL, Goh MS, Tee HW, Trubiano JA, Puy R, Zubrinich CM, Graudins LV. Adverse drug reactions reported by healthcare professionals: reaction characteristics and time to reporting. The Journal of Clinical Pharmacology. 2018 Oct; 58(10):1332-9.
47. Khan SA, Goyal C, Tonpay SD. A study of knowledge, attitudes, and practice of dental doctors about adverse drug reaction reporting in a teaching hospital in India. Perspectives in Clinical Research. 2015 Jul 1; 6(3):144-9.
48. Teja PT, Ramraj B. Study of proportion and pattern of adverse drug events among patients coming to health centers in urban and rural areas. International Journal of Community Medicine and Public Health. 2018 Aug; 5(8):3423.
49. KP S, MG R. Barriers to and facilitators of healthcare professionals in ADR reporting in a tertiary care hospital in India. BMC Health Services Research. 2025 Dec; 25(1):1-9.
50. Roy S, Nandave M, Kumar A. Processing of ADRs. InPharmacovigilance Essentials: Advances, Challenges and Global Perspectives 2024 Apr 4 (pp. 79-109). Singapore: Springer Nature Singapore.
51. Donaldson MS, Corrigan JM, Kohn LT, editors. To err is human: building a safer health system.